C-201Government of CanadaCONSERVATIVE
Pharmaceutical Cost Transparency Act
Tests whether drug-price transparency is a non-partisan issue. Backed by patient-advocacy groups; opposed by industry.
Status
✓
Introduced✓
1st Reading3
2nd Reading4
Committee5
Report6
3rd Reading7
Royal AssentSummary
Conservative private member's bill requiring public disclosure of negotiated drug prices in the pan-Canadian Pharmaceutical Alliance's deals with manufacturers, with a one-year embargo for commercially sensitive details.
Sponsored by
Michael ChongCONSERVATIVE